Research programme: anti-inflammatories - AvicennaAlternative Names: DAV0601
Latest Information Update: 16 Jul 2016
At a glance
- Originator Avicenna Pharma Development
- Mechanism of Action Sphingomyelin phosphodiesterase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Inflammatory bowel diseases; Ulcerative colitis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Ulcerative-colitis in United Arab Emirates (PO, Tablet)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in United Arab Emirates (PO, Tablet)
- 31 Mar 2009 Preclinical trials in Ulcerative colitis in United Arab Emirates (PO)